Effectiveness and Safety of CCoat Intra-Articular Injections in Mild to Moderate Knee Osteoarthritis

NCT ID: NCT05771948

Last Updated: 2024-09-03

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 92 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-03-16
• Study Completion Date: 2025-06-30

Brief Summary

The goal of this clinical trial is to evaluate the Efficacy and Safety of CCoat Intra-Articular Injection in Mild to Moderate Knee Osteoarthritis.

The main questions it aims to answer are:

• To demonstrate superior efficacy of CCoat administered via intra-articular injection versus placebo during the study period.
• To evaluate the efficacy of two different concentrations of CCoat, administered via single IA injection as compared to control group (placebo) One IA injection of CCoat or Placebo will be injected to participants' knee. Follow up will take place up to six months.
• To evaluate the safety of the repeated CCoat injection administered at six months.

Detailed Description

This study aims to assess the effectiveness and safety of intra-articular injection of Aqueous Joint at two different concentrations administered via a single injection in osteoarthritic patients up to 26 weeks of follow-up in a double-blind, randomized clinical study. Additionally, the safety of the repeated injection will be examined.

Primary Effectiveness Objective The primary objective is to demonstrate the superior effectiveness of CCoat administered via single intra-articular injection versus placebo during the study period in terms of functional outcomes as assessed in terms of Pain KOOS subscore at each FU visit (up to and including 12 weeks) and compared to the baseline levels.

Secondary Effectiveness Objective The secondary objective is to assess changes from baseline to 26 weeks in NRS, KOOS symptoms, QOL, ADL and sport subscores. Change from Baseline in Patient's Global Assessment (PGA)) of Osteoarthritis at Week 26 were evaluated. Patients responder rates will be evaluated at 12 and 26 weeks.

Safety Objectives Safety will be evaluated by the occurrence of Adverse Events during the study. Adverse Events will be reported in terms of incidence, severity, and frequency of all Adverse Events (AE).

Clinical Hypotheses The underlying clinical hypothesis of this study is that the CCoat is superior to the control group in terms of KOOS score (Pain, Symptoms, QOL, ADL & Sports) at 3 months compared to baseline, even more in a high concentration.

Conditions

Knee Osteoarthritis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Group 1 (Control)

1 IA injection of 4 ml Normal Saline solution.

Group Type: PLACEBO_COMPARATOR

CCoat

Intervention Type: DEVICE

CCoat is a new intra-articular (IA) injectable joint lubricant for patients suffering from joint pain developed by Liposphere LTD. CCoat is a liposomal boundary lubricant which coats the cartilage surface and protects it from further damage and degradation.

Group 2 (Study)

1 IA injection of 4 ml CCoat

Group Type: EXPERIMENTAL

CCoat

Intervention Type: DEVICE

CCoat is a new intra-articular (IA) injectable joint lubricant for patients suffering from joint pain developed by Liposphere LTD. CCoat is a liposomal boundary lubricant which coats the cartilage surface and protects it from further damage and degradation.

Interventions

CCoat

CCoat is a new intra-articular (IA) injectable joint lubricant for patients suffering from joint pain developed by Liposphere LTD. CCoat is a liposomal boundary lubricant which coats the cartilage surface and protects it from further damage and degradation.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Subject has signed and dated the informed consent form

2. Age ≥30 and ≤ 85 years old

3. Pain in the intended study knee with an average VAS score (active) of ≥3 over the last week before screening.

4. Degenerative changes in the intended study knee that can be categorized as grade I -III- Kellgren Lawrence based upon standing anterior- posterior and lateral radiographsof the knee

5. Body Mass Index (BMI) between 18.5 and 38

6. A negative urine pregnancy test female patient with childbearing potential at Visit 1 prior to intra-articular injection of AqueousJoint.

7. If female, the subject must be either postmenopausal, OR permanently surgically sterile OR for women of childbearing potential using at least 2 methods of birth control that are effective from at least 30 days before Visit 1 through visit 26w (26 weeks post injection).

8. Are willing or able to comply with procedures required in this protocol.

Exclusion Criteria

1. Osteoarthritis of the index knee graded 4 according to the Kellgren-Lawrence Grading

2. History of significant knee trauma or previous surgery of the intended study knee within the last 3 months preceding the screening

3. Pain in both knees with a VAS score of ≥5

4. Intra-articular injection to the intended study knee within 3 months before Screening

5. Significant instability of the index knee

6. Malalignment more than 10 degrees varus OR 10 degrees valgus according to standing X-ray

7. Intake of chronic pain medications (especially opioid pain relievers) without an option to pause for the period of the study

8. History of Psoriatic Arthritis, Rheumatoid Arthritis, or any other inflammatory condition associated with arthritis

9. Wound in the area of the intended study knee

10. Any known tumor of the index knee

11. Any known history of intra-articular or osseous infection of the index knee

12. Any evidence of active infection anywhere in the body. Urinary Tract Infection (UTI) patients can be included following antibiotic treatment, provided that two consecutive cultures are negative (taken within at least 2 weeks of each other)

13. Any known history of inflammatory arthropathy or crystal-deposition arthropathy

14. Any known systemic cartilage and/or bone disorder, such as but not limited to, chondrodysplasia or osteogenesis imperfecta

15. Body Mass Index (BMI) > 38

16. Active malignances, excluding BCC.

17. Chemotherapy and/or radiation in the past 12 months

18. Known history of a severe allergic reaction

19. Patient who is pregnant or intends to become pregnant during the study

20. History of any significant systemic disease, such as but not limited to: HIV, hepatitis, HTLV, syphilis, and coagulopathies

21. A Known substance or alcohol abuse

22. Participation in other clinical trials within 60 days to before the study or concurrent with the study

23. Known insulin dependent diabetes mellitus

24. Unable to undergo X-ray

• Minimum Eligible Age: 30 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Lipo-Sphere

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Michael Drexler, Prof.

Role: PRINCIPAL_INVESTIGATOR

Orthopedic department

Locations

Assuta

Ashdod, , Israel

Site Status: RECRUITING

Sheba Medical Center

Ramat Gan, , Israel

Site Status: RECRUITING

Kaplan Medical Center

Rehovot, , Israel

Site Status: RECRUITING

Countries

Israel

Central Contacts

Alisa Yelisov, SC

Role: CONTACT

alisay@assuta.co.il

972-54-5803409

Facility Contacts

Shai Shemesh, MD

Role: primary

shaishe@assuta.co.il

Tehila Belfer

Role: primary

tehila.biton@sheba.health.gov.il

Shiran Rogof

Role: primary

shiranro1@clalit.org.il

Other Identifiers

CLD-0000616

Identifier Type: -

Identifier Source: org_study_id